{
  "docId": "019de075-ab2a-73e5-980a-7d480707ba09",
  "docSlug": "340a1966b9939070959283ec1665bfbf",
  "documentTitle": "Kymera | Investor Presentation Deck | 60 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 39,
  "pageCount": 60,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 36,
  "notes": "The slide presents longitudinal pharmacodynamic (PD) data for three targets across four dose levels, comparing clinical results to preclinical expectations.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-ab2a-73e5-980a-7d480707ba09/39",
  "deckHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09",
  "deckJsonHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09.json",
  "deckAnchorHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.35,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Target Degradation in PBMC by FLOW",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ddf474d0-935c-417f-9732-d49d3b4a0efd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.62,
        "y": 0.8
      },
      "kind": "disclaimer",
      "text": "These included patients with transformed activated B-cell-like (ABC)-diffuse large B-cell lymphoma (DLBCL)...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "042befc6-b792-4432-aa2c-1f912b511036",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.35,
        "x": 0.62,
        "y": 0.2
      },
      "kind": "list",
      "text": "Five patients treated; 70% KD of IRAK4 and 96-100% KD of Ikaros/Aiolos; DL3-4 expected to be clinically active.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "047da2e9-bc52-4de1-8085-edc9bdb74aec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.2,
        "x": 0.4,
        "y": 0.2
      },
      "kind": "table",
      "text": "Dose level degradation tables for IRAK4, Ikaros, and Aiolos",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d69af6fc-e863-4c94-9d0a-a0141523022f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "DL3 and 4 Degradation Profile of IRAK4, Ikaros and Aiolos Consistent with Strong Antitumor Activity in Preclinical Models",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca51333b-1c36-4a4b-9b72-15c399caf4f9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}